Cardior Pharmaceuticals’ Post

We want to congratulate the 2024 Nobel Prize winners for their remarkable discovery of microRNAs as key regulatory elements in the genome. This milestone has reshaped our understanding of gene regulation and its role in health and disease.   At Cardior, which was acquired by Novo Nordisk earlier in 2024, we are proud to be leading the world’s largest study on microRNA therapeutics in cardiovascular patients. The Nobel Prize-winning discovery of microRNAs forms the foundation of our pioneering work, as we leverage the knowledge to develop therapies that transform cardiovascular care and bring hope to patients in an area with significant unmet needs.   #Cardior #NovoNordisk #miRNA #DrivingChange #NobelPrize2024 #InnovativeMedicine #ScientificBreakthroughs

The Nobel Prize in Physiology or Medicine 2024

The Nobel Prize in Physiology or Medicine 2024

nobelprize.org

Thomas Thum

Professor of Cardiology @ Hannover Medical School, Founder and CSO/CMO @ Cardior Pharmaceuticals | MD, PhD, Heart Disease, RNA enthusiast

1mo

Wonderful to see miRNA therapeutics become reality :-) Congrats to the complete #Cardior and #NovoNordisk teams!

To view or add a comment, sign in

Explore topics